Acting Attorney General Todd Blanche on Thursday signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under federal law, a long-sought change for cannabis advocates. This administrative action, executed in Washington, D.C., means licensed medical cannabis businesses can now deduct standard operating expenses on their federal taxes, a financial relief previously unavailable to them. President Donald Trump pushed his administration to accelerate this policy shift since December, expressing impatience over the timeline.
The reclassification, while not legalizing marijuana for general use across the United States, fundamentally alters the regulatory landscape for medical cannabis. Moving licensed medical marijuana from Schedule I, a category reserved for substances with no accepted medical use and high abuse potential, to Schedule III acknowledges its therapeutic value and lowers federal scrutiny. This change aligns federal policy more closely with the medical marijuana programs established in 40 states. "What this actually means for your family, especially if they are involved in the medical cannabis industry, is a tangible financial benefit," said Maria Rodriguez, a small business owner with a medical cannabis dispensary in Arizona. "For years, we operated at a disadvantage, unable to deduct basic costs like rent or payroll.
This change makes a real difference to our bottom line, allowing us to invest more in patient care and our employees." This specific tax relief addresses a major concern for the industry, which previously operated under Section 280E of the Internal Revenue Code, preventing such deductions. President Trump had directed his administration in December to move swiftly on the reclassification. On Saturday, while signing an unrelated executive order concerning psychedelics, the Republican president indicated frustration with the pace of the process.
Acting Attorney General Blanche stated on Thursday that the Department of Justice was "delivering on President Trump’s promise" to expand Americans' access to medical treatment options. This move, Blanche added in a statement, "allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information."
Beyond the financial implications, the order simplifies the process for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration. Researchers studying cannabis will also find it easier to obtain state-licensed marijuana or derived products for their work without facing federal penalties.
This opens avenues for more rigorous scientific inquiry into the plant's properties and potential applications, a critical step for evidence-based medicine. The policy says one thing: medical marijuana has accepted uses. The reality, however, is that federal law still prohibits recreational use.
Marijuana and marijuana-derived products not distributed through state medical programs will remain classified in Schedule I. This distinction means that while the medical sector gains significant legitimacy and financial relief, the broader federal prohibition on cannabis persists for non-medical applications. government has maintained a longstanding prohibition on marijuana, tracing back to the Marijuana Tax Act of 1937. This federal stance has continued even as nearly all states have adopted some form of cannabis legalization.
California became the first state to adopt a medical marijuana program in 1996. Today, 40 states operate comprehensive medical marijuana systems, while 24 states and Washington, D.C., have authorized adult recreational use. An additional eight states permit low-THC cannabis or CBD oil for medical purposes.
Only Idaho and Kansas ban marijuana entirely. Blanche noted this evolution, writing that the "vast majority of States maintain comprehensive licensing frameworks governing cultivation, processing, distribution, and dispensing of marijuana for medical purposes." He continued, stating that these frameworks "demonstrate a sustained capacity to achieve the public-interest objectives... including protecting public health and safety and preventing the diversion of controlled substances into illicit channels." This acknowledgement from the Justice Department marks a notable shift in federal perception of state-level regulation. The Justice Department under former President Joe Biden had previously proposed reclassifying marijuana, a process that garnered nearly 43,000 formal public comments.
President Trump then ordered the process to advance as quickly as legally permissible. Acting Attorney General Blanche sidestepped the lengthy public review by invoking a provision of federal law that permits the attorney general to determine a drug's classification if required by an international treaty. This procedural maneuver accelerated the reclassification significantly.
Not all political figures supported the change. More than 20 Republican senators, including several staunch Trump allies, sent a letter last year urging the president to maintain the existing Schedule I classification. These lawmakers often express concerns that loosening restrictions could lead to stronger cannabis products and potential public health issues, advocating for more research before any reclassification.
President Trump, despite this action, has made his second term a crusade against other drugs, particularly fentanyl, declaring it a weapon of mass destruction and ordering military actions against suspected drug-carrying vessels, according to AP News reporting. The economic toll extends beyond just federal tax deductions for businesses. The ability to conduct more open research could lead to new medical applications, potentially creating new jobs in pharmaceutical development and clinical trials.
For patients, the long-term hope is for more affordable and accessible medical cannabis products as businesses gain financial stability and research provides clearer dosage and efficacy guidelines. This translates to real-world impacts for working families relying on these medicines. For states where licensed recreational marijuana shops also serve medical patients, the direct impact remains somewhat ambiguous.
In Washington state, for example, 302 of 460 licensed stores hold endorsements allowing them to sell tax-free cannabis products to registered patients, as reported by AP News. This reclassification specifically targets *medical* marijuana. It does not alter federal enforcement or tax rules for recreational sales, creating a nuanced legal environment that states will need to navigate.
Key Takeaways: - State-licensed medical marijuana is now a Schedule III drug, acknowledging its medical utility. - Medical cannabis businesses can now deduct standard operating expenses on federal taxes, a major financial relief. - The reclassification eases barriers for scientific research into cannabis, potentially expanding medical understanding. - This change legitimizes state medical marijuana programs without federally legalizing recreational cannabis. Why It Matters: This policy shift has immediate economic consequences for thousands of cannabis businesses and could accelerate medical research, potentially improving patient access and care. For the first time, the federal government has formally acknowledged the medical value of marijuana, creating a significant divergence between federal and state cannabis policy.
It highlights the ongoing tension between federal prohibition and widespread state-level legalization, affecting everything from tax revenue to public health initiatives across the nation. The Trump administration is launching a new administrative hearing process beginning in June to consider the broader rescheduling of marijuana, extending beyond just the medical applications. This upcoming process could explore further changes to federal cannabis policy.
Businesses, patients, and researchers will be watching closely to see how these discussions unfold and what additional implications might arise for the evolving legal and economic landscape of cannabis in the United States.
Key Takeaways
— - State-licensed medical marijuana is now a Schedule III drug, acknowledging its medical utility.
— - Medical cannabis businesses can now deduct standard operating expenses on federal taxes, a major financial relief.
— - The reclassification eases barriers for scientific research into cannabis, potentially expanding medical understanding.
— - This change legitimizes state medical marijuana programs without federally legalizing recreational cannabis.
Source: AP News
